

Subject Company: Rexahn Pharmaceuticals, Inc. (SEC File No. 001-34079)
Commission File No. for the Related Registration Statement: 333-239702

Alliance Advisors LLC
200 Broadacres Drive, 3rd Fl.
Bloomfield, NJ 07003

PRESCOTT
 FIRST CLASS
 U.S. POSTAGE
PAID
 So. HACKENSACK, NJ
 PERMIT #251

**THIS IS AN IMPORTANT NOTICE
FOR STOCKHOLDERS OF
REXAHN PHARMACEUTICALS, INC.**

Rexahn Pharmaceuticals, Inc. will hold a Special Stockholder Meeting on Nov. 2, 2020 and your account is currently *unvoted*.

**The Board of Directors of
Rexahn encourages you to
vote. Your participation in the
Special Meeting is important!**

At the Nov. 2 Special Meeting, Rexahn Stockholders are being asked to vote **FOR** Proposals to approve a business combination transaction between Rexahn and Ocuphire Pharma, Inc. — a privately held, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of eye disorders.



What can you do to ensure your account is voted?

As a stockholder you can vote today by calling **(855) 643-7453** to speak to a proxy voting specialist.

Don't delay, make the call today.



As a Rexahn Pharmaceuticals, Inc. Stockholder your vote matters now more than ever.

A Special Meeting of Stockholders has been called for November 2, 2020. Rexahn Stockholders are being asked to support all Proposals to help effect a business combination transaction between Rexahn and Ocuphire Pharma, Inc.

The Rexahn Board of Directors recommends you vote FOR the following Proposals:

- ✓ **Proposal 1.** To approve the issuance of shares of Rexahn common stock, \$0.0001 par value per share, to stockholders of Ocuphire pursuant to the terms of the Agreement and Plan of Merger and Reorganization.
- ✓ **Proposal 2.** To approve the plan to effect a reverse stock split of Rexahn common stock, at a ratio ranging from 1-for-3 to 1-for-5.
- ✓ **Proposal 3.** To change the corporate name from "Rexahn Pharmaceuticals, Inc." to "Ocuphire Pharma, Inc."
- ✓ **Proposal 4.** To approve the adoption of the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan.
- ✓ **Proposal 5.** To approve the issuance of: (1.) shares of Rexahn common stock to be issued in the Pre-Merger Financing, and (2.) the issuance of additional shares of Rexahn common stock that may be issued following the closing of the Pre-Merger Financing.
- ✓ **Proposal 6.** To approve an adjournment of the Rexahn special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4 or 5.



Vote your shares today:

call (855) 643-7453 to speak to a proxy voting specialist.